Introduction: Growing evidence has demonstrated that diastolic heart failure occurs in about half of heart failure (HF) patients. We investigated the effects of perindopril on echocardiographic parameters, New York Heart Association (NYHA) functional class and serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels in patients with diastolic heart failure. Methods: In total, 108 diastolic heart failure patients aged ≥ 50 years, who had diastolic dysfunction with an ejection fraction ≥ 50%, were enrolled and randomised to one of the two study groups. Perindopril was initiated in the study group and the control group was given standard therapy. Echocardiographic parameters, NT-proBNP levels and NYHA classes were recorded. The patients were followed for 11 (three to 16) months. Eighty-eight patients completed the study. Results: Although diastolic parameters were not changed, A′ (septal) velocity (10.8 vs 9.9 cm/s) and Sm (septal) velocity (8.5 vs 7.6 cm/s) were significantly increased in the perindopril compared to the control group. A significant increase in A′ (septal) velocity (+0.61 vs -0.28 cm/s, p = 0.04) and a slight increase in Sm (septal) velocity (+0.99 vs 0.36 cm/s, p = 0.054) were noted in the perindopril group. Conclusions: Tissue Doppler septal late diastolic velocities and septal systolic myocardial velocities increased in the perindopril group but NT-proBNP levels, and NYHA class was not changed in this study population.
Heart failure (HF) with normal or preserved ejection fraction (HFpEF), also called diastolic heart failure (DHF), occurs in about half of HF patients. DHF is defined as a clinical syndrome in patients with symptoms and/or signs of HF who have an ejection fraction of ≥ 50%, accompanied by elevated natriuretic peptide levels and relevant structural heart disease (left ventricular hypertrophy and/or left atrial enlargement) or diastolic dysfunction on echocardiography according to 2016 European Society of Cardiology guidelines for heart failure. 1 Diastolic dysfunction (DD) is an important component of HFpEF.
In some previous studies, DD was an inclusion criterion for the study (e.g. PEP-CHF study), whereas it was not a prerequisite in others (e.g. I-PRESERVE or CHARM-Preserved trials). In an echocardiographic sub-study of the CHARM-Preserved trial, 67% of the patients had DD. 2 Left atrial (LA) function, which is a component of diastolic function, is also an important contributor to the pathophysiology of HFpEF. Several previous studies demonstrated that increased LA size and decreased LA systolic function are the most important part of the HFpEF. 3, 4 Parameters indicating LA systolic function may be found abnormal in HFpEF patients during exercise and may correlate with reduced exercise capacity in these patients. 5 There are many ways to assess LA systolic function, such as measurements of LA systolic strain, LA emptying fraction and end-diastolic mitral annular velocity in pulsed tissue Doppler. Doppler tissue imaging of the mitral annulus during atrial systole has been shown to be a practical method to quantify left atrial contractile function. 6 This parameter (Am) correlates well with the changes in LA fractional area, and it therefore provides an easy way to assess LA systolic function.
It has long been evident that this disease is not only a disease of diastolic function. A number of studies have shown that left ventricular longitudinal function, which is a component of systolic function that can be measured as myocardial systolic velocity (Sm) in tissue Doppler echocardiography (TDE), is also reduced in these patients, even though the ejection fraction is within the so-called 'normal' or 'preserved' limits.
AFRICA verapamil, was shown to have some benefit on diastolic function in patients with HFpEF. 14, 15 Recently eplerenone induced improvements in diastolic echocardiographic measures (e.g. E/E′ parameter) in HFpEF patients. 16 In the Hong Kong diastolic heart failure study, both irbesartan and ramipril, added to diuretics in HFpEF patients, increased mean peak systolic (Sm) and early diastolic (Em) mitral annular velocities in TDE. 17 There are also some studies investigating the effects of perindopril on diastolic function in patients with hypertension (HT), diabetes mellitus (DM), or stable coronary artery disease (CAD). [18] [19] [20] In those studies, perindopril improved the parameters of diastolic function in patients with HT and CAD but did not affect diastolic function in diabetic patients.
The effects of perindopril on the echocardiographic parameters of diastolic and systolic function have not been previously investigated in patients with DHF. Given the aforementioned studies, we aimed to investigate the effects of perindopril on the parameters of diastolic left atrial function and longitudinal myocardial function with TDE in patients with DHF. We also investigated whether perindopril treatment changed the NYHA functional class and serum NT-proBNP levels in this study population.
Methods
We enrolled 108 patients with DHF, aged ≥ 50 years, who presented to Izmir Ataturk Education and Research Hospital (IAERH) cardiology out-patient clinics with HF symptoms and were found to have an ejection fraction (EF) of ≥ 50% on transthoracic echocardiography (TTE) accompanied by an evidence of DD on TDE. The HF diagnosis was based on Framingham heart failure criteria.
Exclusion criteria included the following: EF < 50%, patient age < 50 years, severe valvular disease on echocardiography, a history of acute coronary syndrome, atrial fibrillation, cardiomyopathy or pericardial disease, anaemia (serum haemoglobin levels < 10 g/ dl), hyperthyroidism, hypothyroidism, renal insufficiency (serum creatinine > 2 mg/dl or dialysis), serum potassium level > 5.5 mEq/l, moderate to severe pulmonary hypertension (sPAP > 50 mmHg), and/or intolerance to angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), bilateral renal artery stenosis, or any kind of malignancy. Patients with decompensated HF were also excluded.
The patients were randomised into two groups using a basic randomisation method. The first group (perindopril group) was started on oral perindopril treatment (5 mg/day) and the control group received standard DHF treatment alone. None of the patients was using ACEIs or ARBs before enrollment in the study. The study was designed as a randomised and prospective study.
All patients underwent a detailed clinical examination and comprehensive TTE (including TDE) using standardised equipment (Vivid 3 Pro Echocardiography, General Electric Corp, Milwaukee, WI, USA). EF was measured both visually and using the M-mode method. All echocardiographic parameters were measured and recorded.
Blood pressure measurements were taken after 10 minutes of rest. The height and weight of all patients were measured and body mass index (BMI) was calculated. The functional capacity of the patients was assessed according to the NYHA classification system (I-IV). Blood samples were drawn from all patients for biochemistry, complete blood count and NT-proBNP analyses. Blood samples for NT-proBNP measurements were stored in a -70°C refrigerator until the time of analysis, and were analysed using Siemens Corp Immulite-2000 NT-proBNP kites.
The study was approved by the local ethics committee of IAERH and was conducted in accordance with the Declaration of Helsinki.
The patients were followed for a mean period of 11 months (range: three to 16 months). After one month of follow up, blood samples were drawn from all patients for biochemistry analyses and complete blood counts. No significant deteriorations were noted in serum creatinine or potassium levels, and all patients had tolerated the study drug during this period. Accordingly, perindopril dose in the study group was up-titrated to 10 mg/day at the end of one month.
Over the 11-month follow-up period, seven patients decided to withdraw from the study and three patients died. Perindopril was discontinued in 10 patients for different reasons (due to any side effect). Therefore, at the end of the follow-up period, the perindopril group consisted of 37 patients and the control group included 51 patients ( Fig. 1) . At the end of the follow-up period, all patients were invited to the hospital and echocardiographic assessments were repeated. Blood samples were drawn for biochemistry and NT-proBNP measurements. NYHA functional classes were reassessed and recorded.
The primary endpoints of the study were the changes in E′, A′, and Sm velocities, E/E′, E/A, and E′/A′ ratios, isovolumic relaxation time (IVRT) and deceleration time (DT) at the end of the follow-up period. Secondary endpoints included the changes in NT-proBNP levels and NYHA functional classes.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) version 15.0 software program was used for statistical analysis. The Kolmogorov-Smirnov test was used to determine whether the numerical variables were normally distributed. A t-test was used to compare normally distributed variables between the two groups and the Mann-Whitney U-test was conducted for non-normally distributed variables. For categorical variables, cross-tables were made, and chi-squared analysis or Fisher's exact test was performed. The changes from baseline until the end of the 11-month follow-up period were assessed using the Wilcoxon test for non-normally distributed variables and a paired-samples t-test for normally distributed variables. A p-value of < 0.05 was accepted as statistically significant.
Results
The mean age of the patients was 62 years (50-83). Of all patients, 78% were women; 81.8% were hypertensive, and 31% had a history of heart failure. Sixty-one per cent of the patients were receiving CCBs, 39% were receiving beta-blockers, and 55.6% were using diuretics. One per cent of the patients were in NYHA functional class 1, 68% were in NYHA class 2, and 31% were in NYHA class 3. During the 11 months of follow up, seven patients withdrew from the study and three patients died. Perindopril treatment was discontinued in 10 patients due to side effects (dry cough and hypotension). Therefore, at the end of the study period, the perindopril group consisted of 37 patients and the control group included 51 patients. The final analyses of the study were made on the data from 88 patients. The patients in the perindopril group used CCBs more frequently than the patients in the control group (76 vs 51%, p = 0.026). The other clinical and demographic characteristics were similar between the two groups ( Table 1) .
Echocardiographic parameters: At the study baseline, the mean visual EF of the patients was 64%, and the mean EF on M-mode was 65%. Mean left atrial volume index (LAVI) was 24 ml/m 2 . The mean E/A ratio was 0.80, while the average E′ (mean) velocity was 6.5 cm/s. The average A′ (septal) velocity was measured as 10.1 cm/s, whereas A′ (lateral) velocity was 10.2 cm/s and A′ (mean) velocity was 10.2 cm/s. The E/E′ (mean) ratio was 11.2. The average Sm (septal) velocity was 7.2 cm/s, and Sm (lateral) velocity was 7.0 cm/s; Sm (mean) velocity was 7.2 cm/s. Twenty-six per cent of the patients had left ventricular hypertrophy (LVH); 85% had grade 1 DD, and 15% had grade 2 DD. None of the patients had grade 3 DD. There was no significant difference between the two groups in terms of the baseline echocardiographic parameters (Table 2) .
Primary outcomes: At the end of the follow-up period, EF values were similar between the two groups. Mean LAVI values, mean E/A ratios, average E′ (mean) velocities, average A′ (mean) velocities, E/E′ (mean) ratios were also not significantly different between the two groups. LVH was found in 30 and 26% of the patients in the perindopril and control groups, respectively. 
AFRICA
When we compared the echocardiographic parameters of the two groups at the end of the follow-up period, all parameters were comparable except for significant differences noted in A′ (sep), Sm (sep) and Sm (mean) velocities. A′ (sep), Sm (sep) and Sm (mean) velocities were significantly higher in the perindopril group (Table 3) . A′ (sep) velocity in the perindopril group was significantly higher than in the control group (10.8 vs 9.9 cm/s, 95% CI: 0.065-1.795, p = 0.036). Sm (sep) velocity was also elevated in the perindopril group (8.5 vs 7.6 cm/s, 95% CI: 0.127-1.791, p = 0.025). Sm (mean) velocity was also higher in the perindopril group (8.3 vs 7.7 cm/s, 95% CI: 0.046-1.163, p = 0.034). DT and IVRT values were similar between the two groups, which suggested that perindopril treatment did not have a significant effect on these variables.
We also analysed the changes in the echocardiographic parameters from baseline until the end of the follow-up period. For this purpose, we compared the differences in the values recorded at the end of the follow-up period between the two groups. As a result, we found that only the change in the A′ (sep) velocity parameter was statistically significant. In the perindopril group, the A′ (sep) velocity increased, whereas it decreased in the control group. During the study we observed 0.61 cm/s increase in A′ (sep) velocity in the perindopril group and a decrease of 0.28 cm/s in the control group (0.61 vs -0.28 cm/s, 95% CI: 0.039-1.748, p = 0.04). The increase in Sm (sep) velocity in the perindopril group also reached near significance (p = 0.054). The changes observed in the other parameters were not statistically significant (Table 4) .
Secondary outcomes: At the end of the follow-up period, the median NT-proBNP level was 150 pg/ml. In the perindopril group, the median level was 151 pg/ml and in the control group, it was 149 pg/ml. When the two groups were compared, the NT-proBNP levels were not found to be significantly different (p = 0.688 for the comparison of the median values). NT-proBNP levels did not change significantly with perindopril.
At the end of the follow-up period, 57 (65%) patients were in NYHA functional class 2, whereas 31 (35%) were in NYHA class 3. When we compared the two groups, no statistically significant difference was found in terms of the functional capacity at the end of the study (p = 0.184). When we analysed the two groups to determine the change in functional capacity during the follow-up period, no meaningful changes in NYHA functional class were found in either group (Table 5) .
Discussion
HFpEF is a clinical syndrome that is becoming more frequently seen as the population ages worldwide. More strikingly, its mortality rate has not changed for decades while the mortality rate of systolic HF has declined significantly. 21 DD is an important component of HFpEF. Some small studies have reported improvements in DD with some drugs such as CCBs, aldosterone receptor blockers, ACEIs and ARBs in this patient population. [14] [15] [16] [17] However, no previous study assessed the effect of perindopril on diastolic and systolic function in HFpEF patients. The change in the parameters was calculated as the value at 11 months -value at 0 months. Because the meaning of the change in DT and IVRT was different in diastolic dysfunction grades 1 and 2, the comparisons between DT and IVRT values were stratified according to the diastolic dysfunction grade. In this study, we found that perindopril treatment increased tissue Doppler septal late diastolic velocity and slightly increased tissue Doppler septal systolic myocardial velocity in HFpEF patients. It did not improve the E/E′ ratio and tissue Doppler early diastolic velocity, which are markers of increased diastolic pressure in this population. The other diastolic parameters did not improve with perindopril treatment. In fact, only a few studies have reported improvements in systolic or diastolic echocardiographic parameters in HFpEF patients. One of these studies is the Hong Kong Diastolic Heart Failure study, which reported improvements in E′ and Sm velocities with ramipril and irbesartan. 17 It is well known that both E′ and Sm velocities are reduced in HFpEF patients, although EF is within normal limits. [9] [10] [11] [12] [13] Therefore, the systolic function cannot be considered normal in these patients.
The loss of longitudinal function may be compensated for by increased radial motion, which may preserve the EF in HFpEF patients; an effect that is also seen in diabetic patients. 22 The Sm velocity was shown to be a prognostic marker in patients with systemic hypertension and left ventricular hypertrophy, as well as patients with dilated cardiomyopathy. [23] [24] [25] The improvement in septal tissue Doppler myocardial systolic velocity may be an important finding of the present study, although it did not translate into an improvement in EF, likely due to the short duration of follow up. An improvement in EF also may be noticed in the long term.
To the best of our knowledge, this study is the first to show that perindopril treatment improved tissue Doppler systolic function in HFpEF patients. Improvement in systolic function may be related to several mechanisms, including reduction in myocardial fibrosis, left ventricular mass, ischaemia or afterload.
The improvement in tissue Doppler septal late diastolic velocity may also be another important finding of this study. Since this velocity represents LA systolic function in HFpEF patients, perindopril treatment also improved the left atrial function in these patients. This velocity is not the only way to assess left atrial function, but it is a practical way to show the contractile function of the left atrium. 6 Left atrial dysfunction was associated with exercise intolerance in HFpEF patients, 5 so improving this function may decrease exercise dyspnoea, which is an important symptom in these patients. We could not demonstrate symptomatic improvement in our patient group.
Future studies should investigate whether this improvement in left atrial systolic function is also seen during exercise in these patients. It may be more crucial to improve exercise left atrial function since the symptoms are generally exacerbated with exercise. A longer duration of follow up may also show some benefit on symptoms.
The median serum NT-proBNP level of the patients recruited to the present study was 135 pg/ml. This value may be considered low for an HFpEF diagnosis. In reality, there are not clearly defined cut-off values for the diagnosis of this syndrome. In the consensus document of the European Society of Cardiology (ESC) regarding HFpEF published in 2007, natriuretic peptides (NPs) were offered to aid the diagnosis when the E/E′ ratio was between eight and 15. 26 According to this document, an NT-proBNP value > 220 pg/ml supports the diagnosis of HFpEF, but NT-proBNP < 120 pg/ml makes the diagnosis unlikely. In the new 2016 ESC guidelines for heart failure, it is stated that an NT-proBNP value > 125 pg/ml supports the diagnosis of HFpEF. 1 Other studies have also investigated NP levels in DHF patients. In one of those articles, in patients presenting to the out-patient clinic (similar to our study), if the patient's volume status was stable or optivolaemic, NP levels in HFpEF patients may be much lower. 27 A different study that enrolled 159 HFpEF patients reported that 29% of the patients had normal BNP values (≤ 100 pg/ml). These patients were symptomatic and had elevated pulmonary capillary wedge pressures. 28 The authors found that patients with normal BNP levels were younger, were more often female, were mostly obese and had higher BMIs. They concluded that a normal BNP level did not exclude an out-patient diagnosis of HFpEF. Obesity is known to reduce serum NT-proBNP levels, and this trend should be kept in mind when considering a diagnosis of HFpEF. NP levels decline linearly with increasing BMI, and low NP cut-off values should be used for the diagnosis of HFpEF when BMI is increased. 29, 30 In our study, the average BMI of the patients was 33 kg/ m 2 , which might have reduced the NT-proBNP levels. On the other hand, some drugs, such as diuretics and beta-blockers 31 are known to diminish serum NT-proBNP levels.
At the baseline of the present study, 54% of the patients were on diuretic drugs and 35% used beta-blockers. Therefore, concomitant drug use may be an additional factor that decreased baseline NT-proBNP levels. Nevertheless, we believe that the patients we recruited for this study had HFpEF. Framingham criteria were used to diagnose HF, and all patients were required to have evidence of DD on echocardiography, which is an important component of this disease. Another supporting fact not reported in the results section was that 24% of the patients in this study were hospitalised or presented to the emergency room because of HF decompensation during the follow-up period. These data, which are close to the number of hospitalisations characteristic to this population, provide another clue that our patients truly had HFpEF.
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Study limitations
There are many limitations of our study that are worth addressing. First of all, many patients discontinued the study drug or withdrew from the study. Seventeen patients, accounting for 16% of the total study population (20 patients, when three patients who died are also included), were excluded from the study after randomisation due to different reasons. This number may be large for this type of small-size study. The follow-up period may also have been too short to accurately investigate the outcomes associated with the study drug. Over a longer period, the study drug might have shown more pronounced benefits in HFpEF patients. LA systolic function was assessed by tissue Doppler annular late diastolic velocities. This method provides a rapid way to assess LA systolic function, but it might be more accurately assessed by LA systolic strain or LA emptying fraction methods.
Conclusion
Tissue Doppler septal late diastolic velocity and septal systolic myocardial velocity were increased in the perindopril group. NT-proBNP level and NYHA functional status were not changed in this study population.
